Pharmaceutical company Mankind Pharma reported a 39.2% year-on-year rise in net profit to ₹712 crore for the second quarter, up from ₹511.5 crore a year earlier. Revenue from operations increased 17.3% to ₹4,338 crore from ₹3,697.16 crore in the year-ago quarter.
Earnings before interest, taxes, depreciation and amortisation rose 27.1% to ₹1,171 crore from ₹921.3 crore. The EBITDA margin, which measures operating profit as a share of revenue, improved to 27% from 24.9% a year earlier. Separately, Mankind Pharma’s board approved a scheme to merge its wholly owned subsidiaries Prolijune Lifesciences Private Limited and Pavi Buildwell Private Limited into the parent company.
The proposed merger has an appointed date of April 1, 2027, and is subject to the necessary statutory and regulatory approvals, including those from the National Company Law Tribunal , where applicable. The company said the merger qualifies for an exemption from obtaining a no-objection letter from stock exchanges under applicable regulations.
It will, however, submit the scheme to the exchanges for disclosure purposes. The board also took note of a separate proposed merger involving Upakarma Ayurveda Private Limited and Mankind Consumer Products Private Limited , which their respective boards approved on October 26, 2026.
MCPPL is a wholly owned subsidiary of Mankind Pharma, while UAPL is its step-down subsidiary. The proposed merger is subject to the required statutory, regulatory and other approvals. Mankind Pharma shares were trading 4.49% higher at ₹2,312 on the NSE at 3:15 pm IST on October 26, up ₹99.40.